The research team harnessed two large United States-based datasets that together capture a substantial share of the country’s formal treatment activity. The first, the Mental Health Client-Level Data system, aggregates information from mental health treatment providers across the country. The second, the Treatment Episode Data Set Admissions, compiles records from substance use disorder treatment programs. By searching both systems for cases coded as alcohol-induced disorders or substance-induced disorders, the investigators were able to track how frequently these diagnoses appeared over ten consecutive years, and to characterize the clinical profiles of the people behind the numbers.

The headline finding is one of scale rather than saturation. Among all mental health disorder treatment cases recorded during the analytic period, cases involving an alcohol-induced or substance-induced disorder totaled 439,932, representing 0.7 percent of the total. In the substance use disorder treatment data, the counts were larger: alcohol or substance-induced disorders accounted for 459,817 cases, or approximately 2.7 percent of all substance use disorder treatment episodes over the same decade. Those percentages may sound modest, but they translate into hundreds of thousands of individual treatment encounters in which a psychiatric condition was formally attributed to the effects of a psychoactive substance.

The composition of these cases reveals important patterns about which substances are most often implicated. In the substance use disorder treatment data, the overwhelming majority of alcohol-induced disorder cases, 79 percent, were identified as reporting alcohol use, and in 68 percent of those cases alcohol was listed as the primary substance of abuse. This internal consistency matters: it suggests that when clinicians diagnose an alcohol-induced disorder, they are typically doing so in the context of a treatment episode where alcohol is genuinely the dominant problem, rather than as an incidental finding among patients whose primary addiction lies elsewhere.

Opioids tell a different and arguably more alarming story. Heroin and other opiates and synthetics accounted for the primary substance among 28.8 percent of cases with a substance-induced disorder in the substance use disorder treatment data. That nearly three in ten substance-induced disorder cases involved opioids as the primary substance underscores how the opioid crisis has left fingerprints not only on overdose statistics but also on the psychiatric presentation of people entering treatment. Opioid-related induced disorders add a layer of clinical complexity to an already demanding patient population, and the study’s figures suggest that any treatment system planning for opioid-affected patients must also plan for the psychiatric sequelae that opioids can induce.

Perhaps the most clinically revealing findings concern the overlap between substance-induced conditions and depressive disorders. Approximately one in three cases with an alcohol-induced disorder, and one in four cases with a substance-induced disorder, carried a depressive disorder diagnosis within the mental health treatment data. When the researchers looked specifically at primary diagnoses rather than any listed diagnosis, the association remained strong: roughly one in four cases with an alcohol-induced disorder had a depressive disorder as the primary diagnosis, as did 15 percent of cases with a substance-induced disorder. This convergence is not coincidental. Alcohol is a central nervous system depressant, and the neurochemical disruptions it causes can produce or intensify depressive symptoms that persist well beyond intoxication. The data suggest that a meaningful fraction of the depression seen in treatment settings may be entangled with, and in some cases directly produced by, substance use.

The study’s descriptive design is both its strength and its boundary. By drawing on two independent national datasets spanning a decade, the researchers avoided the small samples and single-site biases that plague much of the literature on substance-induced conditions. The sheer volume of cases, nearly 900,000 across the two systems, gives the percentage estimates a solidity that few prior descriptions could claim. At the same time, the authors are careful to frame the work as descriptive: the data summarize who appears in treatment records and with what coded diagnoses, but they cannot establish causal direction for any individual patient. Distinguishing a truly substance-induced depression from a pre-existing depressive disorder that prompted drinking is one of the hardest diagnostic tasks in psychiatry, and administrative datasets cannot fully resolve it.

Even so, the conceptual framework the study rests on has real consequences for how care is delivered. Substance use disorders may arise when individuals use substances to cope with adverse mental health symptoms, and conversely, mental health symptoms can develop because of substance use. These two pathways demand different clinical responses. A depression that will remit with sustained abstinence calls for a different treatment plan than an independent major depressive disorder requiring long-term pharmacotherapy. If substance-induced conditions are under-recognized, patients may receive psychiatric diagnoses that mislabel the source of their suffering; if they are over-applied, genuine independent mental illness may go untreated. Accurate prevalence estimates like those in this study are a prerequisite for getting that clinical calculus right.

The decade-long window also invites reflection on what the numbers do and do not show about trends. The study period encompasses the deepest years of the opioid epidemic, the arrival of fentanyl as the dominant illicit opioid, and the disruptions of the COVID-19 pandemic, all of which reshaped the landscape of American substance use. While the article’s core contribution is the aggregate picture rather than a year-by-year trend analysis, the fact that hundreds of thousands of induced-disorder cases accumulated across both treatment systems over ten years indicates that these are not rare diagnostic curiosities. They are a recurring feature of the treatment caseload that any serious public health accounting of substance-related harm must include.

The authors conclude that substance-induced disorders represent a significant public health concern and that more research is needed to better understand the clinical needs of this population. That call is well founded. The roughly 0.7 percent of mental health cases and 2.7 percent of substance use disorder treatment cases identified here likely represent a floor rather than a ceiling, since diagnostic coding practices vary widely across providers and many affected individuals never enter formal treatment at all. As integrated care models that treat mental health and addiction in the same setting continue to expand, studies like this one provide the epidemiological baseline against which future screening, diagnosis, and treatment efforts can be measured. For clinicians, the message is concrete: when a patient presents with depression alongside heavy alcohol use or opioid dependence, the possibility that the substance is inducing the psychiatric picture deserves explicit consideration, because recognizing it may change the entire course of treatment.

Subject of Research: Epidemiology of alcohol- and substance-induced psychiatric disorders in US mental health and addiction treatment settings, 2013 to 2022

Article Title: Alcohol and substance-induced disorder treatment cases in mental health and addiction treatment facilities from 2013 to 2022: A descriptive study

Article References: Ware, O. D. (2026). Alcohol and substance-induced disorder treatment cases in mental health and addiction treatment facilities from 2013 to 2022: A descriptive study. PLOS Mental Health, 3(9), e0000706. https://doi.org/10.1371/journal.pmen.0000706

Image Credits: AI Generated

DOI: 10.1371/journal.pmen.0000706

Keywords: substance-induced disorders, alcohol-induced disorders, substance use disorder treatment, mental health treatment, depressive disorders, opioids, heroin, Treatment Episode Data Set, Mental Health Client-Level Data, public health, addiction epidemiology, dual diagnosis